Related Experiment Video

Updated: Jun 19, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A point-of-care assay to measure platelet aggregation in patients taking clopidogrel

Dalton S McLean1, Christopher P Cannon

  • 1dsmclean@partners.org

Future Cardiology
|October 7, 2009
PubMed

Insights

Clopidogrel resistance, indicated by poor platelet inhibition, is linked to recurrent ischemic events in patients. The VerifyNow P2Y12 assay can identify these patients, potentially guiding therapy changes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Clopidogrel is crucial for acute coronary syndromes and stenting.
  • Recurrent ischemic events occur despite clopidogrel therapy.
  • Variability in platelet response to clopidogrel contributes to adverse events.

Purpose of the Study:

  • To investigate the utility of the VerifyNow P2Y12 assay.
  • To assess the association between clopidogrel resistance and adverse outcomes.
  • To determine if point-of-care platelet function testing can guide therapy.

Main Methods:

  • Utilized the VerifyNow P2Y12 assay for point-of-care testing.
  • Measured platelet inhibition in patients receiving clopidogrel.
  • Correlated platelet function test results with clinical outcomes.

Main Results:

  • The VerifyNow P2Y12 assay accurately measures platelet inhibition.
  • Identified a significant number of patients with clopidogrel resistance.
  • Linked poor response to clopidogrel with increased risk of ischemic events.

Conclusions:

  • Platelet function testing with VerifyNow P2Y12 can identify clopidogrel resistance.
  • This assay may help personalize antiplatelet therapy.
  • Identifying non-responders could reduce recurrent adverse ischemic events.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide04:50

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide

Published on: August 4, 2023

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...